JP2019521338A - 接触面拡散係数を用いた液体内の疎水性成分の定量方法及びこれを用いた疾患の診断に対する情報提供方法 - Google Patents
接触面拡散係数を用いた液体内の疎水性成分の定量方法及びこれを用いた疾患の診断に対する情報提供方法 Download PDFInfo
- Publication number
- JP2019521338A JP2019521338A JP2018566952A JP2018566952A JP2019521338A JP 2019521338 A JP2019521338 A JP 2019521338A JP 2018566952 A JP2018566952 A JP 2018566952A JP 2018566952 A JP2018566952 A JP 2018566952A JP 2019521338 A JP2019521338 A JP 2019521338A
- Authority
- JP
- Japan
- Prior art keywords
- contact surface
- dementia
- droplet
- fat
- contact
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 239000007788 liquid Substances 0.000 title claims abstract description 48
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 43
- 238000009792 diffusion process Methods 0.000 title claims abstract description 34
- 201000010099 disease Diseases 0.000 title claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 13
- 238000003745 diagnosis Methods 0.000 title description 3
- 239000007787 solid Substances 0.000 claims abstract description 70
- 206010012289 Dementia Diseases 0.000 claims description 48
- 210000002700 urine Anatomy 0.000 claims description 31
- 208000016097 disease of metabolism Diseases 0.000 claims description 26
- 208000030159 metabolic disease Diseases 0.000 claims description 26
- 210000001124 body fluid Anatomy 0.000 claims description 24
- 239000010839 body fluid Substances 0.000 claims description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 238000012937 correction Methods 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 12
- 208000003241 Fat Embolism Diseases 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 201000004810 Vascular dementia Diseases 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 208000010877 cognitive disease Diseases 0.000 claims description 7
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004243 sweat Anatomy 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 70
- 235000019197 fats Nutrition 0.000 description 70
- 238000005259 measurement Methods 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 238000007443 liposuction Methods 0.000 description 17
- 238000004817 gas chromatography Methods 0.000 description 14
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002316 cosmetic surgery Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000005661 hydrophobic surface Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- -1 fatty acid triglycerides Chemical class 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 2
- 235000021081 unsaturated fats Nutrition 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000021080 saturated-trans fats Nutrition 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 235000002316 solid fats Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N13/02—Investigating surface tension of liquids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/003—Diffusion; diffusivity between liquids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N13/02—Investigating surface tension of liquids
- G01N2013/0283—Investigating surface tension of liquids methods of calculating surface tension
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
b)所定の時間(t)が経過した後、上記液滴と上記固体表面との接触面の面積(At)及び上記接触面の直径(dt)を測定する段階と、
c)下記式1に基づいて接触面拡散係数(CADF)を得る段階。
b)所定の時間(t)が経過した後、上記液滴と上記固体表面との接触面の面積(At)及び上記接触面の直径(dt)を測定する段階と、
c)下記式1に基づいて接触面拡散係数(CADF)を得る段階と、
d)上記接触面拡散係数及び下記式2を用いて上記液滴に含まれた脂肪成分の含有量を得る段階と、
e)上記得られた脂肪成分の含有量を正常な人の体液から得た脂肪成分の含有量と比較する段階。
Claims (10)
- a)液体の液滴を固体表面に接触させ、前記液滴と前記固体表面との接触面の初期面積(A0)及び前記接触面の初期直径(d0)を測定する段階と、
b)所定の時間(t)が経過した後、前記液滴と前記固体表面との接触面の面積(At)及び前記接触面の直径(dt)を測定する段階と、
c)下記式1に基づいて接触面拡散係数(CADF)を得る段階と、
を含むことを特徴とする液体に含まれた疎水性成分の定量方法。 - d)前記接触面拡散係数及び下記式2を用いて前記液滴に含まれた疎水性成分の含有量を得る段階をさらに含むことを特徴とする請求項1に記載の液体に含まれた疎水性成分の定量方法。
- 前記液体は体液であることを特徴とする請求項1に記載の液体に含まれた疎水性成分の定量方法。
- 前記体液は血液、血清、血漿、汗及び尿からなる群より選択されることを特徴とする請求項3に記載の液体に含まれた疎水性成分の定量方法。
- 前記疎水性成分は脂肪であることを特徴とする請求項1に記載の液体に含まれた疎水性成分の定量方法。
- a)判断対象の体液の液滴を固体表面に接触させ、前記液滴と前記固体表面との接触面の初期面積(A0)及び前記接触面の初期直径(d0)を測定する段階と、
b)所定の時間(t)が経過した後、前記液滴と前記固体表面との接触面の面積(At)及び前記接触面の直径(dt)を測定する段階と、
c)下記式1に基づいて接触面拡散係数(CADF)を得る段階と、
d)前記接触面拡散係数及び下記式2を用いて前記液滴に含まれた脂肪成分の含有量を得る段階と、
e)前記得られた脂肪成分の含有量を正常な人の体液から得た脂肪成分の含有量と比較する段階と、
を含むことを特徴とする代謝性疾患または認知症の発病の可能性の予測または代謝性疾患または認知症の発病または経過に関する情報提供方法。 - 前記判断対象の体液から得た脂肪成分の含有量と前記正常な人の体液から得た脂肪成分の含有量の差が正数である場合、代謝性疾患または認知症の発病の可能性が高いか、代謝性疾患または認知症の発病を診断することを特徴とする請求項6に記載の代謝性疾患または認知症の発病の可能性の予測または代謝性疾患または認知症の発病または経過に関する情報提供方法。
- 前記体液は血液、血清、血漿、汗または尿からなる群より選択されることを特徴とする請求項6に記載の代謝性疾患または認知症の発病の可能性の予測または代謝性疾患または認知症の発病または経過に関する情報提供方法。
- 前記代謝性疾患は、糖尿病及び脂肪塞栓症からなる群より選択されることを特徴とする請求項6に記載の代謝性疾患または認知症の発病の可能性の予測または代謝性疾患または認知症の発病または経過に関する情報提供方法。
- 前記認知症はアルツハイマー病、パーキンソン病、血管性認知症、混合型認知症及び軽度認知障害からなる群より選択されることを特徴とする請求項6に記載の代謝性疾患または認知症の発病の可能性の予測または代謝性疾患または認知症の発病または経過に関する情報提供方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170053957 | 2017-04-26 | ||
KR10-2017-0053956 | 2017-04-26 | ||
KR20170053956 | 2017-04-26 | ||
KR10-2017-0053957 | 2017-04-26 | ||
PCT/KR2018/004808 WO2018199631A1 (ko) | 2017-04-26 | 2018-04-25 | 접촉면 확산계수를 이용한 액체 내 소수성 성분의 정량 방법 및 이를 이용한 질환의 진단에 대한 정보 제공 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019521338A true JP2019521338A (ja) | 2019-07-25 |
JP6799086B2 JP6799086B2 (ja) | 2020-12-09 |
Family
ID=63918531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018566952A Active JP6799086B2 (ja) | 2017-04-26 | 2018-04-25 | 接触面拡散係数を用いた液体内の疎水性成分の定量方法及びこれを用いた疾患の診断に対する情報提供方法 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP6799086B2 (ja) |
KR (1) | KR102086840B1 (ja) |
WO (1) | WO2018199631A1 (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4958272B2 (ja) * | 2007-01-19 | 2012-06-20 | 学校法人北里研究所 | アルブミン分子のブラウン運動の拡散係数変化に基づく血清または血漿粘度測定方法及び装置 |
JP2008249332A (ja) * | 2007-03-29 | 2008-10-16 | Univ Of Tokushima | 唾液中の脂質・ラフトおよびaqp5を用いた唾液腺機能検査と全身疾患検査法 |
TWI456199B (zh) * | 2011-12-29 | 2014-10-11 | Univ Nat Chiao Tung | 生物檢測裝置及檢測方法 |
KR101992144B1 (ko) * | 2012-10-31 | 2019-06-25 | (주)아모레퍼시픽 | 화장료의 지속성 측정 방법 |
KR101361072B1 (ko) * | 2012-12-17 | 2014-02-10 | 이상현 | 접촉면 확산 계수 기반 액체 내 지방 침투도 측정 방법 |
JP6319856B2 (ja) * | 2014-02-07 | 2018-05-09 | 株式会社フェムトバイオメド | 接触面拡散係数を用いた液体内の脂肪含量測定方法 |
-
2018
- 2018-04-25 KR KR1020180048007A patent/KR102086840B1/ko active IP Right Grant
- 2018-04-25 JP JP2018566952A patent/JP6799086B2/ja active Active
- 2018-04-25 WO PCT/KR2018/004808 patent/WO2018199631A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018199631A1 (ko) | 2018-11-01 |
JP6799086B2 (ja) | 2020-12-09 |
KR102086840B1 (ko) | 2020-03-09 |
KR20180120109A (ko) | 2018-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van de Loo et al. | Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease | |
Stoney et al. | Sex differences in lipid, lipoprotein, cardiovascular, and neuroendocrine responses to acute stress | |
Puig et al. | Lower serum osteocalcin concentrations are associated with brain microstructural changes and worse cognitive performance | |
Schutte et al. | Blood pressure variability is significantly associated with ECG left ventricular mass in normotensive Africans: the SABPA Study | |
EP3417779A1 (en) | Physical condition management device and method for same | |
CN111655151B (zh) | 压力状态的检测方法以及压力检测装置 | |
Sokas et al. | Estimation of heart rate recovery after stair climbing using a wrist-worn device | |
JP6319856B2 (ja) | 接触面拡散係数を用いた液体内の脂肪含量測定方法 | |
Do et al. | Assessing the effects of aging on muscle stiffness using shear wave elastography and myotonometer | |
US20180027214A1 (en) | Contact Area Diffusion Factor for Quantifying Fat Contents of Liquid | |
JP6799086B2 (ja) | 接触面拡散係数を用いた液体内の疎水性成分の定量方法及びこれを用いた疾患の診断に対する情報提供方法 | |
US11165993B2 (en) | Contact area diffusion factor for quantifying fat contents of liquid | |
Ofek et al. | Lower Extremity Position Test: A new clinical quantitative assessment tool of proprioception post stroke | |
US20220386952A1 (en) | Method to determine cognitive impairment | |
CN109313246A (zh) | 自由基消耗速度信息的获取方法以及nash的判定方法 | |
Magierski et al. | Evaluation of the influence of metabolic processes and body composition on cognitive functions: Nutrition and Dementia Project (NutrDem Project) | |
JP2018136327A (ja) | 接触面拡散係数を用いた液体内の脂肪含量測定方法 | |
Walawender et al. | Mobile technology application for improved urine concentration measurement pilot study | |
Uwakwe et al. | Diabetic peripheral neuropathy and its risk factors: a community based study | |
Levine | Quadriceps Muscle Layer Thickness in Kidney Transplant Recipients: A Potential Measure of Frailty and Sarcopenia | |
Jende et al. | Magnetic resonance neurography in spinal cord injury: Imaging findings and clinical significance | |
Patsiris et al. | Detection and Quantification of Exhaled Breath Condensate and Dyspnea Correlation in Stable COPD: A Proof-of-Concept Study | |
Björk | Patch testing with metals with focus on gold | |
Watling | Longitudinal Examination of Peripheral Blood Biomarkers in Healthy Athletes: Implications for Concussion | |
RU2033615C1 (ru) | Способ прогнозирования развития дисциркуляторной энцефалопатии у практически здоровых лиц молодого и среднего возраста |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181220 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191007 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201026 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6799086 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |